Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center College of Medicine, College Station, Texas, USA.
Aging Cell. 2022 Jun;21(6):e13627. doi: 10.1111/acel.13627. Epub 2022 May 10.
Objectively diagnosing age-related cognitive impairment (ACI), mild cognitive impairment (MCI), and early-stage Alzheimer's disease (AD) is a difficult task, as most cognitive impairment is clinically established via questionnaires, history, and physical examinations. A recent study has suggested that monitoring a miRNA triad, miR-181a-5p, miR-146a-5p, and miR-148a-3p can identify ACI and its progression to MCI and AD (Islam et al., EMBO Mol Med. 13: e14997, 2021). This commentary deliberates findings from this article, such as elevated levels of the miRNA triad in the brain impairing neural plasticity and cognitive function, the efficiency of measuring the miRNA triad in the circulating blood diagnosing MCI and AD, and the promise for improving cognitive function in MCI and AD by inhibiting this miRNA triad. Additional studies required prior to employing this miRNA triad in clinical practice are also discussed.
客观诊断与年龄相关的认知障碍（ACI）、轻度认知障碍（MCI）和早期阿尔茨海默病（AD）是一项艰巨的任务，因为大多数认知障碍都是通过问卷、病史和体检在临床上确定的。最近的一项研究表明，监测 microRNA 三联体 miR-181a-5p、miR-146a-5p 和 miR-148a-3p 可以识别 ACI 及其向 MCI 和 AD 的进展（Islam 等人，EMBO Mol Med. 13: e14997, 2021）。本评论讨论了该文章的研究结果，例如大脑中 miRNA 三联体水平升高会损害神经可塑性和认知功能，测量循环血液中 miRNA 三联体来诊断 MCI 和 AD 的效率，以及通过抑制这种 miRNA 三联体来改善 MCI 和 AD 患者认知功能的前景。还讨论了在将该 miRNA 三联体应用于临床实践之前需要进行的其他研究。
